Pfizer Steps up Innovation as Biopharmaceutical Leader
(3BL Media/Justmeans) – Biomedical research and development is one of the world’s most challenging and capital-intensive business processes. It typically takes years before a new breakthrough product reaches patients. But it is also a deeply rewarding process because, at its core, it is about improving the quality of human life.
Pfizer is leading from the front in biomedical R&D, in pursuit of its mission to be the leading edge, innovative biopharmaceutical company by the end of this decade. According to Pfizer’s Chairman and CEO Ian Read, 2015 was a transformational year in the company’s operations. The company advanced 39 proposed therapies in its R&D pipeline, which is now among the strongest in Pfizer's history.
Pfizer has highlighted its achievements in its newly released 2015 integrated annual review, an in-depth look into the company’s financial, social and environmental performance, as told through the voices of Pfizer colleagues. In brief videos and testimonials, Pfizer scientists, researchers and business leaders share how they are working toward measurable change for people whose quality of life is affected by poor health or health risks.
Pfizer has made oncology a priority area for its research efforts. In 2015, the U.S. FDA approved the Ibrance drug for certain cases of metastatic breast cancer in women. The company is addressing the challenges of inflammation and immunology with its pioneering approach involving the use of janus kinase (JAK) inhibitors, which interfere with the inflammation process.
In cardiac care, the company’s development efforts center on bococizumab, a monoclonal antibody that targets a protein interfering with the removal of LDL or bad cholesterol. Bococizumab's extensive lipid-lowering clinical trials continued on pace in 2015 and are expected to complete in 2016.
In 2015, the company’s robust compliance programs continued to guide how it operates to meet the needs of the patients and their families. In the fourth quarter the company launched the “Integrity is...” campaign, which emphasizes individual accountability by encouraging its colleagues to explore what integrity means to them, and to consider how conducting their daily business with integrity is fundamental to Pfizer's success.
The company’s U.S. patient assistance program, Pfizer RxPathways, helped more than 250,000 people access its medicines during 2015. During the year, the company also continued its long-term relationship with the International Trachoma Initiative (ITI). The goal of ITI is to eliminate blinding trachoma by 2020; this is a devastating but completely preventable disease with more than 230 million people at risk in 58 nations.
Pfizer has fostered several other corporate responsibility partnerships including a partnership with GAVI — the global vaccines alliance — to help provide pneumococcal vaccines to children in GAVI countries through 2025 and with the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation to bring Sayana Press, Pfizer's long-acting contraceptive, to women in 69 countries in the developing world.
Pfizer continues to raise awareness through its Get Healthy Stay Healthy platform for health information, which includes television and online content. It reached tens of millions of people, with more than 90 million views of the program's content in 2015.
Image Credit: Flickr via mycolleges